United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - chloramphenicol palmitate (unii: 43vu4207nw) (chloramphenicol - unii:66974fr9q1) - chloramphenicol palmitate 24750 g in 25000 g

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - chloramphenicol palmitate (unii: 43vu4207nw) (chloramphenicol - unii:66974fr9q1) - chloramphenicol palmitate .99 kg in 1 kg

United States - English - NLM (National Library of Medicine)

darmerica, llc - chloramphenicol palmitate (unii: 43vu4207nw) (chloramphenicol palmitate - unii:43vu4207nw) -

United States - English - NLM (National Library of Medicine)

bluebay shandong co.,ltd - chloramphenicol palmitate (unii: 43vu4207nw) (chloramphenicol palmitate - unii:43vu4207nw) -

United States - English - NLM (National Library of Medicine)

bluebay shandong co.,ltd - chloramphenicol palmitate (unii: 43vu4207nw) (chloramphenicol palmitate - unii:43vu4207nw) -

United States - English - NLM (National Library of Medicine)

wang pharmaceuticals & chemicals - chloramphenicol palmitate (unii: 43vu4207nw) (chloramphenicol palmitate - unii:43vu4207nw) -

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - chloramphenicol palmitate (unii: 43vu4207nw) (chloramphenicol palmitate - unii:43vu4207nw) -

United States - English - NLM (National Library of Medicine)

darmerica, llc - chloramphenicol palmitate (unii: 43vu4207nw) (chloramphenicol - unii:66974fr9q1) -

Uganda - English - National Drug Authority

abacus pharma (a) ltd. - chloramphenicol palmitate - oral liquid ordinary suspensions - 125mg/5ml

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - chloramphenicol sodium succinate (unii: 872109hx6b) (chloramphenicol - unii:66974fr9q1) - chloramphenicol 1 g in 10 ml - in accord with the concepts in the   warning box   and this   indications and usage   section, chloramphenicol must be used only in those serious infections for which less potentially dangerous drugs are ineffective or contraindicated.  however, chloramphenicol may be chosen to initiate antibiotic therapy on the clinical impression that one of the conditions below is believed to be present; in vitro sensitivity tests should be performed concurrently so that the drug may be discontinued as soon as possible if less potentially dangerous agents are indicated by such tests.  the decision to continue use of chloramphenicol rather than another antibiotic when both are suggested by in vitro studies to be effective against a specific pathogen should be based upon severity of the infection, susceptibility of the pathogen to the various antimicrobial drugs, efficacy of the various drugs in the infection, and the important additional conce